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Abstract
Study Objective—This study was designed to prospectively evaluate the in vivo activities of
drug transporters, metabolizing enzymes and pharmacokinetics in patients with chronic kidney
diseases (CKD) caused by glomerulonephritis and non-glomerular etiologies.
Design—A prospective study design
Participants—Eighteen adults with CKD
Setting—General Clinical Research Center at the University of North Carolina and University of
Pittsburgh
Measurement and Main Results—Blood and urine were collected and assayed for
fexofenadine (transporter function) as well as flurbiprofen and 4-hydroxyflurbiprofen (CYP2C9
function). CYP3A4 activity was assessed by the erythromycin breath test. In patients with
glomerulonephritis, the apparent oral clearance of fexofenadine (representing transporter activity)
was 58.8±34.4L/h, documenting a 40% reduction compared with previous data in healthy controls.
The CYP2C9 pathway (4-hydroxyflurbiprofen formation clearance), was similar in all the patients
with CKD and was concordant with previous reports of patients with end-stage renal disease
(ESRD) and healthy controls. For flurbiprofen, patients with glomerulonephritis had higher oral
clearance than those with nonglomeruler CKD, suggesting higher unbound fraction and enhanced
metabolism through other (non-CYP2C9) routes. No statistically significant differences in
CYP3A4 activity were observed in either group of patients, or when compared with results from
previous studies of patients with ESRD or healthy controls.
Conclusions—The current study suggests no statistically significant differences in the in vivo
activity of CYP2C9 and CYP3A4 in patients with either glomerulonephritis or non-glomerular
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CKD. However, there are clinical differences in transporter function as defined by at least a 25%
reduction in activity in glomerulonephritis as opposed to healthy controls. A similarity in the in
vivo function between patients with glomerulonephritis and ESRD, and between patients with
glomerulonephritis and non-glomerular CKD was present despite significant differences in kidney
function. Further in vivo and in vitro studies are necessary to fully understand the physiologic and
disease-specific nuances that contribute to alterations in drug disposition in patients with kidney
diseases.
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Introduction
Chronic kidney disease (CKD) affects more than 26 million people in the United.States. 1
According to the National Institutes of Health, the three leading etiologies for end-stage
renal disease (ESRD) are diabetes mellitus (39%), hypertension (29%), and
glomerulonephritis (5%). 2 While it is well established that CKD can result in decreased
elimination of drugs via the kidneys, the effects of the disease on nonrenal clearance
processes such as specific metabolic or transport routes are less well described.
Experimental models of CKD have reported reductions in protein and mRNA expression of
hepatic cytochrome P450 (CYP) enzymes including CYP3A1, CYP3A2, CYP2C11, and N-
acetyltransferases. 3–5 Various alterations in activity of drug transporters in the kidney have
been reported in a CKD model in rats. 6 Reductions in nonrenal clearance in patients with
CKD range from 30% to 67% for substrates of the CYP3A4, CYP2D6, CYP2B6, and
CYP2C9 enzymes and transporter pathways. 7 In order to fully understand the significance
of alterations in protein levels and activity of metabolic and transport pathways in patients
with CKD, it is important to evaluate the effects that specific forms of the disease, such as
glomerulonephritis, have on these pathways and whether these alterations influence drug
disposition in a clinically relevant manner.
Numerous studies have reported various probe drugs or probe drug combinations (e.g.,
cocktails) as a direct approach to evaluate the in vivo function of drug-metabolizing
enzymes and transporters. 8–10 However, only a few studies have been conducted in patients
with CKD. 11–14 Thus, applicability of the results from most published studies beyond the
healthy control population remains to be established. As patients with CKD are commonly
prescribed 10–12 different medications on a daily basis15, alterations in one or more
pathway important for drug disposition could have profound effects on prescribed therapies.
Hence, studies that evaluate the activity of various drug metabolism pathways should
address requirements for modifications in drug regimens and the interaction potential with
other commonly prescribed drugs used in the targeted disease populations. There is a
particular interest in the CYP3A4 and CYP2C9 enzymes in patients with
glomerulonephritis, as these enzymes are important in the metabolic activation of the
majority of drugs commonly prescribed to patients with CKD, including cyclophosphamide.
The primary purpose of the current study was to prospectively evaluate the activity of drug
transporter and the CYP3A4 and CYP2C9 metabolizing enzyme pathways and
pharmacokinetics in patients with CKD caused by glomerulonephritis. In performing these
assessments, we investigated the clinical pharmacokinetics of flubiprofen, a pharmacologic
probe of CYP2C9 metabolism; fexofenadine, a nonspecific probe of drug transport; and
erythromycin, a probe of CYP3A4 metabolism in vivo. Previous results by our group
indicated reductions in CYP2B6 activity (assessed by bupropion) in patients with
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glomerulonephritis compared with other subject groups. 16 A secondary objective of the
study was to compare the activity of CYP3A4 and CYP2C9 and drug transport in
glomerulonephritis compared with nonglomerular CKD and with previous published reports
in healthy controls and in patients with ESRD.
Methods
Patients
Patients with CKD caused by biopsy-confirmed glomerulonephritis due to either systemic
lupus erythematosus (SLE) nephritis or small vessel vasculitis (SVV) consented to
participate in an IRB-approved study to assess the in vivo activity of drug transport and drug
metabolism (CYP2C9 and CYP3A4) pathways.(Figure 1) A small comparator group of
patients with nonglomerular CKD were also evaluated.(Figure 1) At the 72-hour study visit,
all of the patients with glomerulonephritis received intravenous cyclophosphamide treatment
as part of standard care and an antiemetic regimen, which consisted of oral dexamethasone
and ondansetron. Concomitant therapy with other immunosuppressants was allowed.
Patients who were unable to abstain from ingestion of alcohol, orange juice, and grapefruit
juice for at least 48 hours prior to and during the study were excluded from study
participation. Eligibility criteria included the following: normal liver function, stable kidney
function, and a negative urine pregnancy test result for women of child-bearing potential.
Patients taking drugs (and doses) known to interfere with the metabolism of any of the probe
substrates, and those with a known allergy or sensitivity to any of the probe substrates, were
also excluded. All patients were required to undergo an overnight fast prior to study
initiation and were provided with a CYP450 diet (exclusion of cruciferous vegetables,
spinach, garlic, grapefruit, char-grilled meats, and smoked meats) throughout the study. 17
Clinical data, including serum creatinine concentration, estimated creatinine clearance
(Clcr) 18, urinary protein to creatinine ratio (UP:Cr), and serum albumin concentration were
measured at the time of the study or abstracted from the medical record within 30 days of
the study, when available. The study and consent form were approved by the Biomedical
Review Boards at both the University of North Carolina at Chapel Hill and the University of
Pittsburgh.
Pharmacokinetic Study
For the pharmacokinetic study, patients with glomerulonephritis were admitted to the
General Clinical Research Center (GCRC) at the University of North Carolina for a 72-hour
inpatient stay. Prior to the start of the cyclophosphamide infusion, these patients received
one tablet each concomitantly of fexofenadine (60 mg) to assess transporter function and
flurbiprofen (50 mg) to assess CYP2C9 activity, followed by 8 ounces of water. Several
hours prior to the cyclophosphamide infusion, patients received intravenous 14C-
erythromycin (3 µCi) to assess the activity of CYP3A4. The intravenous 14C-erythromycin
(3 µCi) was diluted in 0.9% sodium chloride and administered over 60 seconds. Breath
samples were collected into foil balloons at baseline and at 20 minutes to determine
CYP3A4 activity. Patients with nonglomerular CKD were studied at the GCRC at the
University of Pittsburgh and received only flurbiprofen and 14C-erythromycin. To serve as a
comparison with results obtained from the glomerulonephritis patients, we identified
previous historical studies reporting fexofenadine, flurbiprofen, and erythromycin
phenotyping in ESRD and healthy controls.9,13,19,20 Serial blood samples (0.5, 1, 2, 3, 4, 6,
8, 12, 18, 24, 36, 48, 72 h) were drawn into heparinized vacutainers (7.5mL) for assessment
of fexofenadine and/or flurbiprofen. Heparinized blood samples were centrifuged
immediately for 10 minutes at 4°C, and plasma was transferred to plastic screw top tubes
and stored at −80°C until assay. Urine volume for each collection period was recorded, and
2 mL aliquots were stored at −80°C until analysis.
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Plasma fexofenadine concentrations were determined by validated methods employing
liquid chromatography tandem mass spectrometry as recently described.21 The assay was
linear over the concentration range of 1.0 to 500 ng/ml; the precision and accuracy (intra-
and interrun) were within 4.3% and 8.0%, respectively.
Flurbiprofen plasma concentrations were determined by liquid chromatography tandem
mass spectrometry. Briefly, plasma samples were processed by protein precipitation with
acetonitrile with flurbiprofen-d3 used as the internal standard. An aliquot of the processed
sample was injected onto a Supelco Discovery HS F5 analytical column (2.1 mm × 50 mm,
3 µM). Binary gradient elution was achieved with high-performance liquid chromatography
mobile phases comprising 1 mM acetic acid in water and 1 mM acetic acid in acetonitrile
with a flow rate of 0.2 ml/min. The LC/MS/MS system consisted of a Surveyor HPLC
autosampler, Surveyor MS quaternary pump and a TSQ Quantum Discovery triple
quadrupole mass spectrometer (Thermo, San Jose, CA). The TSQ Quantum mass
spectrometer was equipped with an electrospray (ESI) source and operated in the negative
ion mode. The acquisition parameters were: spray voltage 3.0 kV, source collision-induced
dissociation 10 V and heated capillary temperature of 350°C. The collision energy was 10
eV for all analytes. The selected reaction monitoring scheme followed transitions of the [M
+H]+ precursor to selected product ions with the following values: m/z 243.1 > 199.0 for
flurbiprofen and m/z 246.1 > 202.0 for flurbiprofen-d3. The standard concentrations ranged
from 0.025 mg/mL to 10 mg/mL. The intra- and interday precision (coefficient of variation)
and accuracy (relative error) values were within 11% for the low, medium and high
flurbiprofen quality control concentrations.
The amount of 14CO2 exhaled in the collected breath samples was quantified by liquid
scintillation counting (Packard 1600, Hewlett Packard, Palo Alto, CA).
Pharmacokinetic Analysis
Noncompartmental pharmacokinetic analyses of fexofenadine and flurbiprofen were
conducted using WinNonlin v4.1 (Pharsight, Mountain View CA) with the linear up-log
down method for area under the curve (AUC) determination. The following parameters for
fexofenadine and flurbiprofen were reported: observed concentration maximum (Cmax), time
to maximum concentration (Tmax), half-life (T1/2), area under the plasma concentration vs
time curve from 0-∞ hours (AUC 0-∞), and apparent oral clearance (Cl/F). For flurbiprofen,
the amount of drug and metabolite in the urine (Ae) was calculated by multiplying the
measured concentration by the total urine volume for each collection period (0–6, 6–12, 12–
18, 18–24, 24–36, 36–48, 48–72 hours). The Ae over the study period was computed by
adding the Ae for the relevant collection intervals. Renal clearance (Clr) for flubiprofen was
calculated by Ae 0-end of last collection/ AUC 0-last blood sample. The formation clearance of 4-
OH flurbiprofen was calculated as the amount of 4-OH flurbiprofen in
urine (0-end of last collection) / flurbiprofen AUC0-last blood sample (e.g. 72 hours), based on the
assumption that all of the 4-OH flubiprofen that is formed is immediately excreted
unchanged in the urine. The metabolism rate of the administered 14C erythromycin dose (3
µCi) was expressed as the percent of administered dose exhaled per hour.
Statistics
Descriptive analyses for pharmacokinetic parameters, demographic variables, and clinical
laboratories for the glomerulonephritis cohort included mean values and standard deviations,
as appropriate. Analysis of Variance (ANOVA), with Tukey’s post-hoc test, was used to
assess the statistical significance of differences in the pharmacokinetic parameters for
fexofenadine, flurbiprofen, and 14C-erythromycin activity between patient groups. Mean
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±standard deviation pharmacokinetics data from published studies of healthy controls and
ESRD patients were used for comparison with our experimental CKD data.
A post-hoc sample size analysis was conducted based on the primary comparison analysis
for the secondary study measure - the differences in apparent oral clearance of the probe
drugs between glomerulonephritis and healthy controls. For fexofenadine, seven patients per
group with expected standard deviations of 30 L/h would have 80% power. For flurbiprofen
and 14C erythromycin, 12 patients per group with expected standard deviations of 1 L/h and
1% of dose metabolized per hour, respectively, would have 80% power.
All data are presented as mean ± standard deviation and were analyzed by Instat v3.0
(GraphPad, Inc, La Jolla, CA); p values <0.05 were considered statistically significant.
Results
Patient Demographics
A total of 12 patients with biopsy-confirmed glomerulonephritis were enrolled (SLE =5;
SVV =7). Patients with non-glomerular CKD (n=6) were also enrolled. The etiologies for
CKD in this later group were diabetes mellitus (n=2), hypertension (n=1), other (n=1),
unknown (n=2). The patient demographics are presented in Table 1. The non-Caucasian
patients with glomerulonephritis included five African Americans, one Hispanic and one
“other” patient. A total of eight patients with glomerulonephritis were receiving
glucocorticoids 24±19 mg per day (range 15mg to 60mg daily). The patients with non-
glomerular CKD were older (64±17 vs 41±17), and all four of the non-Caucasians were
African Americans. The demographics of the healthy patients with ESRD and the healthy
controls in the published studies were similar to the experimental CKD study groups.
In Vivo Phenotyping for Transporter, CYP2C9, and CYP3A4 Activity
The mean (±standard deviation) pharmacokinetic parameters for fexofenadine and
flurbiprofen in all study and referenced control groups are provided in Tables 2 and 3,
respectively. Significant differences in fexofenadine pharmacokinetic parameters were noted
across patient groups. Tukey post-hoc tests were used to evaluate specific differences
between comparison groups. Patients with glomerulonephritis had significantly longer
fexofenadine half-life values (11.5±5.6 hours) than for patients with ESRD (4.6±1.3 hours;
p<0.001) or healthy controls (3.4±0.9 hours; p<0.001). Patients with glomerulonephritis
patients had lower dose-corrected fexofenadine Cmax values (140±83 ng/mL) than healthy
controls (232±97 ng/mL; p<0.05). Significant differences in flurbiprofen pharmacokinetic
parameters were noted across patient groups for Cmax, Tmax, half-life, AUC and Cl/F
(Table 3). 9,20 Patients with glomerulonephritis had significantly lower flurbiprofen Cmax
values (3.1±1.3 µg/mL) than both non-glomerular CKD patients (6.6±1.5 µg/mL; p<0.01)
and healthy controls (9.4±2.5 µg/mL;p<0.001. 9 Flurbiprofen Tmax values were greater in
glomerulonephritis patients (4.8±2.1 hours) as compared to non-glomerular CKD (1.7±0.8
h; p<0.001), ESRD (2.3±1.2; p<0.01), and healthy controls (2.3±1.0 h; p<0.01).9,20 Higher
flurbiprofen apparent oral clearance values (1.9±0.5 L/h) were demonstrated in patients with
glomerulonephritis compared with patients who had non-glomerular CKD (0.9±0.3 L/h;
p<0.001) and the healthy controls (1.1±0.4 L/h; p<0.001. 9 The 4-OH flurbiprofen formation
clearance was similar across the experimental CKD populations and healthy controls.
The erythromycin breath test results (CYP3A4 activity) were reported as percentage (%)
dose metabolized per hour: glomerulonephritis 2.0±0.8% (n=12), ESRD 1.9±0.7%
(n=12) 13, non-glomerular CKD 2.2±0.6% (n=6), and healthy controls 2.7±1.0% (n=12) 13.
No significant differences (p=0.0996) were observed between groups.
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This is the first study to evaluate the influence of glomerulonephritis on the in vivo activity
of transport proteins (as reflected by fexofenadine disposition) and drug metabolizing
enzymes (CYP2C9 and CYP3A4). It is important to elucidate drug metabolism and transport
activity in patients with glomerulonephritis to inform clinicians about possible dosing
changes for drugs that are substrates for the affected routes. Typical clinical manifestations
of glomerulonephritis include combined reductions in kidney function [e.g. glomerular
filtration rate (GFR)], and structural abnormalities [e.g. urinary protein excretion often in the
nephrotic range (≥3.5 g/day)]. Patients with severe proteinuria may exhibit enhanced
filtration of large molecular weight substances including plasma proteins 22, which can
result in disruption of elimination characteristics for small molecule drugs. 23 In addition,
reduced concentrations of serum albumin may alter the disposition of drugs that are
significantly bound to albumin. 23–25
A composite measure of drug transport activity was provided by an assessment of
fexofenadine apparent oral clearance. Fexofenadine is a P-glycoprotein substrate that is
eliminated unchanged in the feces (80%) and urine (10%), and is 5% bound to plasma
proteins. Previous research has identified fexofenadine as an in vivo P-glycoprotein
phenotyping probe. 26–28 Additionally, the International Transporter Consortium included
fexofenadine as an in vivo P-glycoprotein probe. 29 However, some data published after the
current study commenced indicate that in addition to P-glycoprotein, the organic anion
transporting polypeptides (OATPs) 30,31 and multidrug resistance associated proteins
(MRPs) 32,33, are also involved in fexofenadine disposition. Thus, the specificity of
fexofenadine as a P-glycoprotein probe may be somewhat limited.
In order to provide comparisons of drug pharmacokinetics between subjects with
glomerulonephritis, non-glomerular CKD, ESRD, and healthy controls, the experimental
and published pharmacokinetics data were evaluated. While there are limitations to this
approach, such as differences in assay specificity and limits of quantification, the
information gained from this approach can be of considerable value when exploring
differences, justifying future studies, and informing clinical decision making. The apparent
oral clearance of fexofenadine in the glomerulonephritis population was lower than in
healthy controls and higher than in ESRD patients, although only the comparison with
healthy controls was statistically significant. There appear to be no currently published
fexofenadine pharmacokinetics data from patients with non-glomerular CKD for
comparison. Significantly longer half-life and lower Cmax values were observed in patients
with glomerulonephritis as compared with published values in ESRD patients. 19
Additionally, patients with glomerulonephritis had significantly longer half-life values of
fexofenadine than the healthy control population.19 The longer fexofenadine half-life in
glomerulonephritis patients as compared with ESRD patients and healthy controls could be
due to an increase in the volume of distribution. Decreased apparent oral clearance could
also be contributing to the long half-life in patients with glomerulonephritis.
A number of mechanisms could be responsible for the 40% decrease in apparent oral
clearance of fexofenadine including: 1) decreased intestinal efflux due to P-glycoprotein,
resulting in an increase in systemic exposure, 2) increased intestinal OATP1A2-mediated
uptake, resulting in an increase in systemic exposure, 3) decreased hepatic OATP1B1 or
OATP1B3 uptake, 4) decreased hepatic and renal P-glycoprotein-mediated excretion, or 5)
increased (non-P-glycoprotein) renal or hepatic efflux by transporters on the basolateral
membrane of proximal tubular cells. Common P-glycoprotein inhibitors prescribed for the
glomerulonephritis population include proton pump inhibitors (e.g. omeprazole,
pantoprazole, lansoprazole), simvastatin, and fluoxetine. Combined use of these drugs could
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amplify the effects of glomerulonephritis on transporter function. However, none of the
glomerulonephritis patients included in the study had received these agents.
The activity of the CYP2C9 drug metabolism pathway was assessed by flurbiprofen, a low
extraction ratio drug that is highly protein bound (99%) to albumin and eliminated via the
kidneys as metabolites, primarily as 4-hydroxyflurbiprofen. The CYP2C9 pathway accounts
for the metabolism of approximately 20% of marketed drugs, 34 including drug classes such
as nonsteroidal anti-inflammatory drugs (NSAIDs), angiotensin II receptor blockers,
sulfonylureas, and warfarin. Several CYP2C9 inhibitors, e.g. fluvastatin, lovastatin,
sertraline, and sulfamethoxazole, are commonly used in patients with glomerulonephritis.
The current study found that flurbiprofen pharmacokinetics were similar in patients with
glomerulonephritis and those with ESRD and were different from patients with non-
glomerular CKD and normal controls. 20 Kidney function assessments, as defined by
creatinine clearance, demonstrated that patients with glomerulonephritis had essentially
normal kidney function (102±43 mL/min), but had flurbiprofen pharmacokinetics that were
similar to patients with ESRD. Patients with glomerulonephritis had lower flurbiprofen
Cmax values than patients with non-glomerular CKD patients or the healthy controls.
Possible explanations for the lower flurbiprofen Cmax values include: 1) decreased
bioavailability, 2) increased volume of distribution, or 3) increased clearance. 20 We did not
assess bioavailability or volume of distribution, but higher apparent oral clearance values
were noted in the patients with glomerulonephritis as compared to data in patients with non-
glomerular CKD and healthy controls. Increased apparent oral clearance was not due to
increased formation clearance of 4-hydroxyflurbiprofen, as indicated by the nonsignificant
differences between comparator groups.
Laboratory data from the current study revealed serum albumin concentrations that were
two-fold less in patients with glomerulonephritis (2.0±0.2 g/dL) as compared with patients
with non-glomerular CKD (3.9±0.3 g/dL). This is a factor that could contribute to increased
total drug clearance and volume of distribution, and lower total plasma concentrations (e.g.
Cmax). End stage renal disease is reported to alter the clearance of highly bound drugs
through uremia-induced changes in albumin binding. 35,36 Higher apparent oral clearance
values in glomerulonephritis and ESRD patients could be a reflection of a higher unbound
fraction of flurbiprofen. The increase in apparent oral clearance most likely occurs through
metabolism pathways other than 4-OH flurbiprofen, given the similar formation clearance
values.
CYP3A4 is the predominant metabolic pathway for pharmaceutical products. Several
CYP3A4 probes including erythromycin (via the erythromycin breath test) 37, midazolam 38,
and 6-β-hydroxycortisol/cortisol ratio 39, have been used to assess the in vivo activity of this
important drug-metabolizing enzyme. In the current study, the erythromycin breath test was
selected to assess CYP3A4 in vivo activity over the other common probes because of its
safety profile and the presence of glucocorticoid therapy in a proportion of the
glomerulonephritis population. Glucocorticoids can induce some metabolism enzymes,
including CYP3A4; however, this did not likely affect the study analysis given that
CYP3A4 activity in glomerulonephritis was actually reduced, to a similar extent as
previously reported in patients with ESRD. These results suggest that factors in
glomerulonephritis other than reductions in GFR could be reducing the activity of the
CYP3A4 metabolism pathway. Systemic lupus erythematosis (SLE) and SVV are
inflammatory conditions and there are data to support reductions in CYP enzyme activity
under conditions of inflammation. 40,41 A recent publication reported that OATP uptake
transporters and the P-glycoprotein efflux transporter influence the disposition of
erythromycin in humans 42, suggesting reduced applicability of the erythromycin breath test
results to other CYP3A4 substrates that induce or inhibit these transport proteins.
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The current study provides data demonstrating the activity of transport and drug metabolism
(CYP3A4 and CYP2C9) pathways in patients with CKD due to glomerulonephritis. There
were no statistically significant differences in the in vivo activity for CYP3A4 and CYP2C9
between patient groups. However, there were clearly clinically relevant differences between
patients with glomerulonephritis and healthy controls, as defined by a change of 25% for the
two pathways. Additionally, several significant pharmacokinetic differences were noted
between patients with glomerulonephritis and healthy controls, as well as with other
comparison groups. An interesting finding was the similarity between the in vivo function
across drug metabolism and transport routes between the glomerulonephritis, nonglomerular
CKD, and ESRD patients, despite having significant differences in kidney function. Further
in vivo and in vitro studies are necessary to fully understand the physiologic and disease-
specific nuances that contribute to alterations in drug disposition between patients with
various forms of kidney diseases.
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Table 1





Gender (F/M) 9/3 1/5
Race (Caucasian/NonCaucasian) 5/7 2/4
Age (years) 41±17 64±17
Weight (kg) 91.2±17.5 85.8±24.2
Serum Creatinine (mg/dL) 1.3±0.7 3.1±2.0
Creatinine Clearance (mL/min) 102±43 29±18
Urinary Protein:Urinary Creatinine 1.6±1.5 0.2±0.2
Serum Albumin (g/dL) 2.0±0.2 3.9±0.3
Creatinine clearance calculated by Cockcroft and Gault 18
CKD – chronic kidney disease
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Table 2
Pharmacokinetics of fexofenadine in three different populations. Data presented as mean ±standard deviation.
Glomerulonephritis
(n=12)






140±83c 232±97a,d 134 ± 65a 0.0200
Tmax, h 4.6±3.0 2.0 2.0 ND
T1/2, h 11.5±5.6e,f 4.6±1.3 3.4 ± 0.9 <0.0001
AUC0-∞,
ng h/mL
1351±723 1963±922a, g 690 ± 337a 0.0016
Cl/F, L/h 58.8±34.4h 37.9±19.5g 103 ± 38 0.0001
a
dose adjusted to 60 mg
b
Overall p value by ANOVA
Results of Tukey’s post-hoc analysis:
c
glomerulonephritis vs. ESRD; p<0.05
d
ESRD vs. healthy controls; p<0.05
e
glomerulonephritis vs ESRD; p<0.001
f
glomerulonephritis vs healthy controls; p<0.001
g
ESRD vs healthy controls; p<0.01
h
glomerulonephritis vs healthy controls; p<0.01
Data presented as means or mean±standard deviation
ESRD – end stage renal disease
ND – not done
NR – not reported
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